Noopept vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Noopept is a potent dipeptide-derived nootropic from Russia, structurally related to piracetam but estimated to be 1,000 times more potent by mass. It enhances memory consolidation, learning, and recall while providing neuroprotection via BDNF and NGF upregulation.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- ~5–10 minutes but metabolite (CPG) effects last hours
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- Oral, Sublingual, Intranasal
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 10–30 mg
- 300-600 mcg
- Frequency
- 1–2x daily
- Once daily
- Key Benefits
- Enhances memory formation and recall
- Improves learning speed and cognitive processing
- Neuroprotective via BDNF/NGF upregulation
- Anxiolytic at low-to-moderate doses
- Improves verbal fluency and information processing
- Antioxidant (reduces oxidative damage in neurons)
- May improve cognitive symptoms of mild cognitive impairment
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Headaches (choline depletion — pair with choline source)
- Irritability or anxiety at high doses
- Overstimulation
- Rare: brain fog with chronic use
- +1 more
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —